MedTrace Logo

Effect of BIA 9-1067 on Rasagiline Pharmacokinetics

NCT01532128 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2015-08-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the effect of BIA 9-1067 on rasagiline pharmacokinetics in healthy subjects.

Conditions

  • Parkinson Disease

Interventions

DRUG

rasagiline

1 mg rasagiline (single-dose)

DRUG

BIA 9-1067

50 mg BIA 9-1067 (single-dose)

Sponsors & Collaborators

  • Bial - Portela C S.A.

    lead INDUSTRY

Principal Investigators

  • Béatric Astruc, MD · Biotrial - Human Pharmacology Unit

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-02-28
Completion
2010-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01532128 on ClinicalTrials.gov